SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
SGP Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
SpyGlass Pharma, Inc. Common StockNASDAQ: SGP
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin of $6.85M in Q1 FY2026
Q1 FY2026 selling, general & admin was $6.85M.
What to watch
Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.85M+15.7% QoQ
- Last fiscal yearDec 2025
- $12.2M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | — | -100.0% | — |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 12.2M USD
- Year-over-year change
- —
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.2M | — |
Selling, General & Admin vs competitors
How SGP compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $3.64B USD | +8.6% | +4.0% | 33.3% | |
| LTM Jun 2026 | $2.22B USD | +1.8% | +14.8% | 41.8% | |
| LTM Jun 2026 | $386.7M USD | +34.7% | +19.5% | 63.1% | |
| LTM Apr 2026 | $177.31M USD | -11.1% | +9.5% | 61.1% | |
| LTM Mar 2026 | $124.38M USD | +14.7% | +17.9% | 239.0% | |
| LTM Mar 2026 | $115.87M USD | +8.5% | +24.3% | 90.9% | |
| LTM Mar 2026 | $91.48M USD | -7.4% | -9.4% | 115.0% | |
| LTM Mar 2026 | $53.04M USD | +1.3% | -5.0% | 696.5% | |
| LTM Mar 2026 | CHF 27.55M CHF | +39.2% | +54.0% | 5466.6% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $12.2M USD | — | — | — |
| Peer median (excluding SGP) | — | +8.5% | +14.8% | 90.9% | |
Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2025 Dec 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | 612K |
| Gross Profit | (612K) |
| Gross Margin | — |
| Research & Development | 28.64M |
| Selling, General & Admin | 12.2M |
| Operating Expenses | 40.84M |
| Depreciation & Amortization | 612K |
| EBITDA | (39.26M) |
| EBITDA Margin | — |
| Operating Income | (41.45M) |
| Operating Margin | — |
| Interest Income | 3.11M |
| Interest Expense | 0 |
| Other Income / Expenses | 1.58M |
| Income Before Tax | (39.87M) |
| Pre-Tax Margin | — |
| Income Tax Expense | 0 |
| Net Income | (39.87M) |
| Net Margin | — |
| EPS (Basic) | (1.19) |
| EPS (Diluted) | (1.19) |
| Weighted Avg Shares | 33.43M |
| Weighted Avg Shares (Diluted) | 33.43M |
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.